武文娣,刘大卫,李克莉,郑景山,许涤沙,王亚敏,曹雷,曹玲生,袁平,王华庆,李黎

• 1:中国疾病预防控制中心免疫规划中心

摘要(Abstract)：

目的分析中国2012年疑似预防接种异常反应(Adverse Events Following Immunization,AEFI)(未包括香港、澳门特别行政区和台湾地区,下同)的发生特征,评价AEFI信息管理系统运转情况及预防接种安全性。方法通过中国AEFI信息管理系统,收集截至2013年8月21日报告的2012年发生的AEFI个案数据,采用描述流行病学方法进行分析。结果中国2012年AEFI信息管理系统共收到105 519例个案,比2011年增加了38.80%。中国共有2824个县(区、市、旗,下同)有数据报告,占总县数的91.21%;48h内报告率为98.48%;在10 291例需要调查的AEFI中,48h内调查率为99.14%。AEFI报告数男、女性别比为1.39∶1;≤1岁占74.10%。根据中国2012年免疫规划信息管理系统中疫苗接种剂次估算,AEFI总发生率为21.71/10万剂,严重AEFI估算发生率为0.18/10万剂,预防接种异常反应估算发生率为1.62/10万剂,严重预防接种异常反应估算发生率为0.11/10万剂。不良反应中,一般反应以发热、红肿、硬结为主,预防接种异常反应以过敏性皮疹、卡介苗淋巴结炎为主。不良反应主要集中在接种后≤1d。在所有AEFI中,治愈和好转的占99.03%,死亡96例,其中预防接种异常反应20例。结论中国AEFI监测的敏感性有较大提高,但西部地区部分省(自治区、直辖市)仍是薄弱地区;AEFI常发生在小年龄儿童和接种后≤1d;国家免疫规划疫苗预防接种异常反应报告发生率均在预期发生范围内。

关键词(KeyWords)： 疑似预防接种异常反应;监测

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 武文娣,刘大卫,李克莉,郑景山,许涤沙,王亚敏,曹雷,曹玲生,袁平,王华庆,李黎

参考文献(References)：

• [1]卫生部,国家食品药品监督管理局.全国疑似预防接种异常反应监测方案[S].2010-06-03.Ministry of Health,State Food and Drug Administration of the People's Republic of China.National Guideline for the Surveillance of Adverse Events Following Immunization[S].2010-06-03.
• [2]武文娣,李克莉,郑景山,等.中国2011年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2013,19(2),97-109.WU Wen-di,LI Ke-li,ZHENG Jing-shan,et al.Analysis on Surveillance Data of Adverse Events Following Immunization in China,2011[J].Chinese Journal of Vaccines and Immunization,2013,19(2),97-109.
• [3]卫生部.预防接种异常反应鉴定办法[S].2008-12-01.Ministry of Health of the People's Republic of China.Identification Method for Adverse Reaction Following Immunization[S].2008-12-01.
• [4]刘大卫,郭飚,曹玲生,等.全国2005~2006年疑似预防接种异常反应监测分析[J].中国计划免疫,2007,13(6):505-513.LIU Da-wei,GUO Biao,CAO Ling-sheng,et al.Study on the Surveillance of Adverse Events Following Immunization in China,2005-2006[J].Chinese Journal of Vaccines and Immunization,2007,13(6):505-513.
• [5]武文娣,刘大卫,吴冰冰,等.全国2007~2008年疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2009,15(6):481-490.WU Wen-di,LIU Da-wei,WU Bing-bing,et al.Analysis on the Surveillance of Adverse Events Following Immunization in China,2007-2008[J].Chinese Journal of Vaccines and Immunization,2009,15(6):481-490.
• [6]武文娣,刘大卫,李克莉,等.全国2009年疑似预防接种异常反应监测分析[J].中国疫苗和免疫,2011,17(2):99-108.WU Wen-di,LIU Da-wei,LI Ke-li,et al.Analysis on Adverse Events Following Immunization Surveillance in China,2009[J].Chinese Journal of Vaccines and Immunization,2011,17(2):99-108.
• [7]武文娣,刘大卫,李克莉,等.中国2010年疑似预防接种异常反应监测数据分析[J].中国疫苗和免疫,2012,18(5):385-397.WU Wen-di,LIU Da-wei,LI Ke-li,et al.Analysis on Adverse Events Following Immunization Surveillance in China,2010[J].Chinese Journal of Vaccines and Immunization,2012,18(5):385-397.
• [8]Young June Choe,Geun-Ryang Bae.Management of vaccine safety in Korea[J].Clin Exp Vaccine Res,2013,40(2):40-45.
• [9]N MacDonald,L Pickering.Canada's eight-step vaccine safety program:Vaccine literacy[J].Paediatr Child Health,2009,14(9):605-608.
• [10]Weigong Zhou,Vitali Pool,John K,et al.Surveillance for Safety After Immunization:Vaccine Adverse Event Reporting System(VAERS)—United States,1991-2001[J].MMWR,2003,52(No.SS-1):1-24.
• [11]Public Health Agency of Canada.Canadian National Report on Immunization,2006[S].2006-11-01.
• [12]Deepika M,Jane C,Peter B,et al.Annual Report:Surveillance of Adverse Events Following Immunization in Australia,2011[J].CDI,2012,36(4):315-332.
• [13]谢广中,刁连东,王树巧,等.预防接种的反应和处理[M].第3版,上海:上海科学技术出版社,2009:113-115.XIE Guang-zhong,DIAO Lian-dong,WANG Shu-qiao,et al.Response to the Reactions after Vaccination[M].Third Edition,Shanghai:Shanghai Science and Technology Press,2009:113-115.
• [14]WHO&WPRO.Immunization safety surveillance:guidelines for immunization program managers on surveillance of adverse events following immunization(Second Edition)[S].Manila,Philippines,2013.
• [15]WHO.Mass measles immunization campaigns:reporting and investigating adverse events following immunization[S].Geneva,Swiss,2002.
• [16]Robert E Weibel,David E Benor.Reporting Vaccine-Associated Paralytic Poliomyelitis:Concordance between the CDC and the National Vaccine Injury Compensation Program[J].Am J Public Health,1996,86:734-737.
• [17]Hauck LJ,White C,Feasby TE,et al.Incidence of Guillain-Barrésyndrome in Alberta,Canada:an administrative data study[J].J Neurol Neurosurg Psychiatry,2008,79:318-320.
• [18]Juurlink DN,Stukel TA,Kwong J,et al.Guillain-Barrésyndrome after influenza vaccination in adults:a population-based study[J].Arch Intern Med,2006,166:2217-2221.
• [19]Steven B,Juhani E,Claire-Anne S,et al.Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1influenza vaccines[J].Public Health.Published online October 31,2009 DOI:10.1016/S0140-6736(09)61877-61878.
• [20]Tetsuo N,Kazumasa O.Vaccine adverse events reported in postmarketing study of the Kitasato Institute from 1994 to 2004[J].Vaccine,2007,25(3):570-576.
• [21]Chakravarty A.Neurologic illness following post-exposure prophylaxis with purified chick embryo cell ant rabies vaccine[J].J Assoc Physicians India,2001,49:927-928.
• [22]常利民,刘大卫,李克莉,等.全国2008~2010年接种疫苗后过敏性休克监测结果分析[J].中国疫苗和免疫,2012,18(5):398-401.CHANG Li-min,LIU Da-wei,LI Ke-li,et al.Analysis of Anaphylactic Shock Monitoring Data Following Vaccination in 2008-2010[J].Chinese Journal of Vaccines and Immunization,2012,18(5):419-434.